Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Work In Process: 2021-2024

Historic Work In Process for RedHill Biopharma (RDHL) over the last 4 years, with Dec 2024 value amounting to $308,000.

  • RedHill Biopharma's Work In Process rose 32.19% to $308,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $308,000, marking a year-over-year increase of 32.19%. This contributed to the annual value of $308,000 for FY2024, which is 32.19% up from last year.
  • As of FY2024, RedHill Biopharma's Work In Process stood at $308,000, which was up 32.19% from $233,000 recorded in FY2023.
  • In the past 5 years, RedHill Biopharma's Work In Process ranged from a high of $5.2 million in FY2021 and a low of $233,000 during FY2023.
  • In the last 3 years, RedHill Biopharma's Work In Process had a median value of $308,000 in 2024 and averaged $975,333.
  • As far as peak fluctuations go, RedHill Biopharma's Work In Process plummeted by 90.23% in 2023, and later skyrocketed by 32.19% in 2024.
  • Yearly analysis of 4 years shows RedHill Biopharma's Work In Process stood at $5.2 million in 2021, then crashed by 54.09% to $2.4 million in 2022, then crashed by 90.23% to $233,000 in 2023, then spiked by 32.19% to $308,000 in 2024.